Mark Bachleda
Plus aucun poste en cours
Fortune : 2 277 $ au 30/04/2024
Profil
Mark J.
Bachleda worked as a Vice President at Bristol Myers Squibb Co. and as a Vice President-Sales & Account Management at Juno Therapeutics, Inc. He also worked as a Chief Commercial Officer at Galera Therapeutics, Inc. from 2021 to 2023.
Bachleda holds an MBA from the University of California, Berkeley and a doctorate from the University of Illinois.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/04/2023 | 11 000 ( 0,02% ) | 2 277 $ | 30/04/2024 |
Anciens postes connus de Mark Bachleda
| Sociétés | Poste | Fin |
|---|---|---|
| GALERA THERAPEUTICS, INC. | Corporate Officer/Principal | 09/08/2023 |
| JUNO THERAPEUTICS INC | Sales & Marketing | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Mark Bachleda
| University of Illinois | Doctorate Degree |
| University of California, Berkeley | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GALERA THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |